Spyre Therapeutics reported early Phase 2 results for SPY001 in ulcerative colitis, saying the program met the study’s primary objective after 12 weeks. The company disclosed a statistically significant 9.2-point reduction in a disease activity scoring system and reported remission and endoscopic imaging improvements alongside a safety update that included one severe adverse event not attributed to the drug. SPY001 targets the α4β7 pathway, an approach linked to established mechanisms in inflammatory bowel disease while Spyre positions the asset to deliver longer-lasting effects. The company also said additional proof-of-concept data from other therapies in the study are expected later this year. The update matters commercially because multiple players are racing toward combination regimens and improved differentiation versus established biologic classes, and early signals can affect partnering and capital allocation.